"GSK's $1.4 Billion Deal to Acquire Aiolos Bio Strengthens Respiratory Portfolio"
GSK has entered into an agreement to acquire Aiolos Bio for $1 billion upfront and up to $400 million in milestone payments, gaining access to AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody. This acquisition expands GSK’s respiratory pipeline and offers the potential to redefine the standard-of-care for asthma treatment, with AIO-001 targeting the TSLP pathway and demonstrating initial safety and tolerability in early studies. The transaction is subject to regulatory clearances and underscores GSK’s commitment to advancing respiratory therapies.